Novoris (Risperidone)

Risperidone works by blocking dopamine D2 receptors and serotonin 5‑HT2A receptors. This dual antagonism reduces excess dopamine activity that contributes to psychosis while modulating serotonin pathways that affect mood and behavior, leading to symptom improvement.

The dose of risperidone is individualized. A qualified prescriber determines the appropriate starting dose, titration schedule, and maintenance dose based on the patient’s age, diagnosis, response, and tolerability. No fixed regimen is provided here.

Risperidone is classified as a pregnancy category C drug, meaning risk cannot be ruled out. It should be used only if the potential benefit justifies the potential fetal risk. Risperidone is excreted in breast milk, so breastfeeding mothers should discuss alternatives with their healthcare provider.

To request Novoris, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and required import documentation.

Compared with typical antipsychotics, risperidone offers a lower risk of extrapyramidal side effects while providing effective control of psychotic symptoms. Relative to other atypicals, it has a modest metabolic impact but a higher propensity for prolactin elevation. Choice of therapy depends on efficacy, side‑effect profile, patient history and clinician judgment.

Novoris tablets should be stored at ambient temperature below 25 °C. Keep them in the original packaging, protect from moisture and direct light, and ensure the container is tightly closed to maintain product stability.

Novoris is supplied as oral tablets. The tablet should be swallowed whole with a glass of water and can be taken with or without food. Patients should follow the dosing schedule prescribed by their healthcare professional.

Serious risks include tardive dyskinesia (potentially irreversible movement disorder), neuroleptic malignant syndrome (fever, muscle rigidity, autonomic instability), agranulocytosis (dangerously low white‑blood‑cell count), and significant metabolic changes such as weight gain, hyperglycaemia, and dyslipidaemia.

Novoris should not be used by individuals with known hypersensitivity to risperidone or any component of the tablet. It is also contraindicated in patients with severe central nervous system depression, uncontrolled cardiovascular disease, or those taking medications that strongly inhibit CYP2D6 without appropriate monitoring.